secwatch.observer — SEC 8-K summary
======================================

Issuer:     NovoCure Ltd (NVCR)
CIK:        0001645113
Form:       8-K
Filed at:   2024-01-18T23:59:59+00:00
Accession:  0001645113-24-000005
Event type: regulatory
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA accepts Novocure's PMA for TTFields in NSCLC post-platinum; decision H2 2024
--------------------------------------------------------------------------------

- PMA application accepted for filing; FDA begins substantive review.
- Submission filed Dec 15, 2023; regulatory decision expected in second half 2024.
- TTFields therapy plus standard systemic therapies for NSCLC after progression on platinum-based therapy.
- CEO states milestone brings therapy closer to patients with few non-toxic options.
- Application based on LUNAR trial data in post-platinum NSCLC.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1645113/000164511324000005/0001645113-24-000005-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1645113/000164511324000005/nvcr-20240118.htm
  HTML page:      https://secwatch.observer/filing/0001645113-24-000005

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer